NASDAQ:EPZM Epizyme (EPZM) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free epzm Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.47▼$1.4750-Day Range$1.47▼$1.5252-Week Range$0.41▼$5.80Volume7,960 shsAverage Volume3.23 million shsMarket Capitalization$247.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Epizyme alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Epizyme Stock (NASDAQ:EPZM)Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! EPZM Stock News HeadlinesNovember 1, 2023 | morningstar.combluebird bio Inc BLUEMarch 22, 2023 | thestreet.comCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. August 12, 2022 | nasdaq.comAptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - NasdaqAugust 12, 2022 | streetinsider.comForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comAugust 10, 2022 | finance.yahoo.comThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableAugust 9, 2022 | benzinga.comEpizyme: Q2 Earnings Insights - BenzingaAugust 9, 2022 | businesswire.comEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business WireApril 23, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.August 9, 2022 | apnews.comEpizyme: Q2 Earnings SnapshotAugust 5, 2022 | seekingalpha.comIpsen extends tender offer date in Epizyme deal to get US antitrust clearance - Seeking AlphaAugust 5, 2022 | businesswire.comIpsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 - Business WireJuly 28, 2022 | finance.yahoo.comIpsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance - Yahoo FinanceJuly 26, 2022 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR NewswireJuly 16, 2022 | benzinga.comShareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO - BenzingaJuly 14, 2022 | prnewswire.comSHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations - PR NewswireJuly 14, 2022 | benzinga.comEPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM - BenzingaJuly 13, 2022 | streetinsider.comForm SC 14D9 Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comJuly 11, 2022 | gurufocus.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - GuruFocus.comJuly 10, 2022 | globenewswire.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, RADA, EPZM - GlobeNewswireJuly 6, 2022 | prnewswire.comMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm - PR NewswireJuly 6, 2022 | seekingalpha.comEpizyme Acquisition By Ipsen: CVR Value (NASDAQ:EPZM) - Seeking AlphaJuly 5, 2022 | prnewswire.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM - PR NewswireJuly 5, 2022 | marketscreener.comEpizyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comJuly 1, 2022 | streetinsider.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - StreetInsider.comJuly 1, 2022 | benzinga.comEPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the FirmJune 29, 2022 | gurufocus.comEPIZYME INVESTOR ALERT by the - GuruFocus.comSee More Headlines Receive EPZM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EPZM CUSIPN/A CIK1571498 Webwww.epizyme.com Phone(617) 229-5872Fax617-349-0707Employees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-251,120,000.00 Net Margins-391.90% Pretax Margin-391.80% Return on Equity-2,459.33% Return on Assets-69.74% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.19 Sales & Book Value Annual Sales$37.43 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-2.72Miscellaneous Outstanding Shares168,329,000Free Float128,968,000Market Cap$247.44 million OptionableOptionable Beta-0.41 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Grant C. Bogle (Age 64)Pres, CEO, Principal Financial Officer & Director Comp: $923.32kDr. Jeffery L. Kutok M.D. (Age 55)Ph.D., Chief Scientific Officer Comp: $646.13kDr. H. Robert HorvitzCo-Founder & Chairman of the Scientific Advisory BoardDr. Yi ZhangScientific Co-Founder & Member of The Scientific Advisory BoardMr. Jerald Korn J.D. (Age 43)Chief Operating Officer Mr. Joseph Beaulieu (Age 41)Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer Mr. Craig West CFAVP of Investor RelationsMr. John F. Weidenbruch (Age 61)Sr. VP, Gen. Counsel & Sec. Ms. Tanja WeberChief Bus. OfficerDr. Mark A. De Rosch Ph.D. (Age 58)Chief Regulatory Officer More ExecutivesKey CompetitorsTelomir PharmaceuticalsNASDAQ:TELOPuma BiotechnologyNASDAQ:PBYI2seventy bioNASDAQ:TSVTAC ImmuneNASDAQ:ACIUXeris BiopharmaNASDAQ:XERSView All Competitors EPZM Stock Analysis - Frequently Asked Questions How were Epizyme's earnings last quarter? Epizyme, Inc. (NASDAQ:EPZM) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.16. The biopharmaceutical company earned $5.20 million during the quarter, compared to analysts' expectations of $8.65 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 391.90%. The business's quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.55) earnings per share. What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX). This page (NASDAQ:EPZM) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
